Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration
October 10, 2023 03:00 ET | Salipro Biotech AB
Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization of monoclonal antibodies
GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
October 10, 2023 03:00 ET | GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its...
Stacked logo.png
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
October 10, 2023 02:30 ET | Sosei Group Corporation
The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry...
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023 07:32 ET | Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
September 29, 2023 07:30 ET | Structure Therapeutics Inc.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
Vaccinex logo
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
September 28, 2023 08:00 ET | Vaccinex, Inc.
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select...
Vaccinex logo
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023 08:00 ET | Vaccinex, Inc.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023 16:05 ET | Structure Therapeutics Inc.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
August 03, 2023 17:32 ET | Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Orion Biotechnology
Orion Biotechnology Completes Discovery of First-in-Class Molecule Against Undrugged GPCR Target in Four Months
July 18, 2023 11:33 ET | Orion Biotechnology Canada Ltd.
Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...